This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clinical Laserthermia Systems Future Growth

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clinical Laserthermia Systems.

56.9%

Earnings growth rate

50.0%

EPS growth rate

Medical Equipment earnings growth	27.0%
Revenue growth rate	56.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	24 Feb 2023

No updates

No updates

Earnings and Revenue Growth Forecasts

OM:CLS UR B - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	115	-2	N/A	N/A	1
12/31/2024	44	-45	-48	-45	1
12/31/2023	17	-70	-70	-67	1
3/31/2023	6	-78	-71	-68	N/A
12/31/2022	6	-71	-69	-68	N/A
9/30/2022	3	-81	-81	-81	N/A
6/30/2022	2	-63	-66	-66	N/A
3/31/2022	2	-68	-71	-71	N/A
12/31/2021	2	-64	-67	-66	N/A
9/30/2021	1	-60	-63	-63	N/A
6/30/2021	2	-57	-55	-55	N/A
3/31/2021	2	-47	-41	-41	N/A
12/31/2020	1	-58	-56	-55	N/A
9/30/2020	1	-58	-54	-53	N/A
6/30/2020	2	-57	-54	-54	N/A
3/31/2020	6	-54	-52	-52	N/A
12/31/2019	6	-43	-39	-39	N/A
9/30/2019	6	-38	-37	-36	N/A
6/30/2019	5	-37	-35	-34	N/A
3/31/2019	1	-41	-44	-43	N/A
12/31/2018	8	-33	-41	-39	N/A
9/30/2018	10	-28	-33	-31	N/A
6/30/2018	11	-24	-33	-31	N/A
3/31/2018	12	-15	-29	-24	N/A
12/31/2017	8	-21	-29	-24	N/A
9/30/2017	8	-22	-34	-29	N/A
6/30/2017	8	-26	-28	-24	N/A
3/31/2017	6	-27	-24	-23	N/A
12/31/2016	4	-27	N/A	-20	N/A
9/30/2016	1	-27	N/A	-19	N/A
6/30/2016	0	-23	N/A	-22	N/A
3/31/2016	0	-20	N/A	-17	N/A
12/31/2015	N/A	-17	N/A	-19	N/A
9/30/2015	0	-21	N/A	-21	N/A
6/30/2015	0	-20	N/A	-20	N/A
3/31/2015	0	-20	N/A	-19	N/A
12/31/2014	N/A	-18	N/A	-16	N/A
9/30/2014	0	-16	N/A	-18	N/A
6/30/2014	N/A	-16	N/A	-18	N/A
3/31/2014	N/A	-17	N/A	-17	N/A
12/31/2013	N/A	-18	N/A	-18	N/A
9/30/2013	0	-16	N/A	-13	N/A
6/30/2013	N/A	-15	N/A	-12	N/A
3/31/2013	0	-13	N/A	-11	N/A
12/31/2012	N/A	-13	N/A	-12	N/A
9/30/2012	0	-11	N/A	-10	N/A

Earnings vs Savings Rate: CLS UR B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLS UR B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLS UR B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLS UR B's revenue (56.5% per year) is forecast to grow faster than the Swedish market (5.5% per year).

High Growth Revenue: CLS UR B's revenue (56.5% per year) is forecast to grow faster than 20% per year.

Future ROE: Insufficient data to determine if CLS UR B's Return on Equity is forecast to be high in 3 years time